Loading...

We've got a brand new version of Simply Wall St! Try it out

NanoSphere Health Sciences

CNSX:NSHS
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NSHS
CNSX
CA$11M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

NanoSphere Health Sciences Inc., a nano-biotechnology company, focuses on providing delivery of nutritive elements and medicants through licensing arrangements. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • NanoSphere Health Sciences has significant price volatility in the past 3 months.
NSHS Share Price and Events
7 Day Returns
-4.8%
CNSX:NSHS
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-74%
CNSX:NSHS
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
NSHS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NanoSphere Health Sciences (NSHS) -4.8% -20% -50% -74% - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • NSHS underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • NSHS underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

NSHS Value

 Is NanoSphere Health Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NanoSphere Health Sciences. This is due to cash flow or dividend data being unavailable. The share price is CA$0.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NanoSphere Health Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NanoSphere Health Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:NSHS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.04
CNSX:NSHS Share Price ** CNSX (2019-09-20) in CAD CA$0.1
CNSX:NSHS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.08
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NanoSphere Health Sciences.

CNSX:NSHS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:NSHS Share Price ÷ EPS (both in USD)

= 0.08 ÷ -0.04

-1.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoSphere Health Sciences is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • NanoSphere Health Sciences is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does NanoSphere Health Sciences's expected growth come at a high price?
Raw Data
CNSX:NSHS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NanoSphere Health Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NanoSphere Health Sciences's assets?
Raw Data
CNSX:NSHS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.01
CNSX:NSHS Share Price * CNSX (2019-09-20) in CAD CA$0.1
CNSX:NSHS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $0.08
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:NSHS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:NSHS Share Price ÷ Book Value per Share (both in USD)

= 0.08 ÷ 0.01

7.61x

* Primary Listing of NanoSphere Health Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoSphere Health Sciences is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess NanoSphere Health Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. NanoSphere Health Sciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NSHS Future Performance

 How is NanoSphere Health Sciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoSphere Health Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NanoSphere Health Sciences expected to grow at an attractive rate?
  • Unable to compare NanoSphere Health Sciences's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare NanoSphere Health Sciences's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare NanoSphere Health Sciences's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:NSHS Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:NSHS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:NSHS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -2 -4
2019-03-31 0 -3 -4
2018-12-31 0 -3 -5
2018-09-30 1 -3 -12
2018-06-30 0 -3 -11
2018-03-31 -2 -11
2017-12-31 -1 -10
2016-12-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if NanoSphere Health Sciences is high growth as no earnings estimate data is available.
  • Unable to determine if NanoSphere Health Sciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:NSHS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from NanoSphere Health Sciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:NSHS Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.04
2019-03-31 -0.04
2018-12-31 -0.05
2018-09-30 -0.12
2018-06-30 -0.12
2018-03-31 -0.11
2017-12-31 -0.90
2016-12-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NanoSphere Health Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. NanoSphere Health Sciences's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. NanoSphere Health Sciences's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess NanoSphere Health Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NanoSphere Health Sciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NSHS Past Performance

  How has NanoSphere Health Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NanoSphere Health Sciences's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NanoSphere Health Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare NanoSphere Health Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NanoSphere Health Sciences's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
NanoSphere Health Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NanoSphere Health Sciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:NSHS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.11 -3.96 2.41 0.13
2019-03-31 0.30 -4.25 2.84 0.13
2018-12-31 0.04 -4.51 2.89 0.12
2018-09-30 0.58 -11.74 2.66
2018-06-30 0.20 -11.34 2.02 0.06
2018-03-31 -10.69 1.48 0.06
2017-12-31 -9.91 1.04 0.06
2016-12-31 -0.51 0.51
2015-12-31 0.02 -1.01 0.74
2014-12-31 0.01 -0.53 0.23 0.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NanoSphere Health Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NanoSphere Health Sciences has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NanoSphere Health Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NanoSphere Health Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NanoSphere Health Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NSHS Health

 How is NanoSphere Health Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NanoSphere Health Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NanoSphere Health Sciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • NanoSphere Health Sciences has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NanoSphere Health Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • NanoSphere Health Sciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NanoSphere Health Sciences Company Filings, last reported 2 months ago.

CNSX:NSHS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1.07 0.00 0.31
2019-03-31 1.63 0.00 0.66
2018-12-31 0.84 0.00 0.21
2018-09-30 1.58 0.00 0.12
2018-06-30 2.09 0.00 1.07
2018-03-31 2.78 0.00 2.29
2017-12-31 3.68 0.00 3.70
2016-12-31 -0.33 0.57 0.44
2015-12-31 -0.42 0.47 0.04
2014-12-31 -0.30 0.30 0.01
  • NanoSphere Health Sciences has no debt.
  • NanoSphere Health Sciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NanoSphere Health Sciences has less than a year of cash runway based on current free cash flow.
  • NanoSphere Health Sciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 50.2% each year.
X
Financial health checks
We assess NanoSphere Health Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NanoSphere Health Sciences has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NSHS Dividends

 What is NanoSphere Health Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NanoSphere Health Sciences dividends.
If you bought CA$2,000 of NanoSphere Health Sciences shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NanoSphere Health Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NanoSphere Health Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:NSHS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NanoSphere Health Sciences has not reported any payouts.
  • Unable to verify if NanoSphere Health Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NanoSphere Health Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NanoSphere Health Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NanoSphere Health Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NanoSphere Health Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NanoSphere Health Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NSHS Management

 What is the CEO of NanoSphere Health Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark Percival
TENURE AS CEO 0.3 years
CEO Bio

Dr. Mark Percival has been the Chief Executive Officer at NanoSphere Health Sciences Inc. since June 2019. Dr. Percival has extensive experience in the healthcare field across two continents and has led important innovations for more than three decades. Dr. Percival has become an inspirational leader and a very special resource in healthcare innovation and value-based care.

CEO Compensation
  • Insufficient data for Mark to compare compensation growth.
  • Insufficient data for Mark to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the NanoSphere Health Sciences management team in years:

0.5
Average Tenure
36
Average Age
  • The average tenure for the NanoSphere Health Sciences management team is less than 2 years, this suggests a new team.
Management Team

Richard Kaufman

TITLE
Co-Founder
COMPENSATION
$146K
AGE
69

Bennett Liu

TITLE
Chief Financial Officer
COMPENSATION
$30K
AGE
25
TENURE
2.3 yrs

Stephanie Hopper

TITLE
Director & COO
COMPENSATION
$3K
TENURE
0.7 yrs

Mark Percival

TITLE
Chief Executive Officer
TENURE
0.3 yrs

Terry Grossman

TITLE
Co-Founder & Chief Medical Director

Victor Goncalves

TITLE
Executive Vice President
COMPENSATION
$40K
AGE
36
TENURE
0.2 yrs

Kate Wells

TITLE
Chief Marketing Officer of NanoSphere Health Sciences
Board of Directors Tenure

Average tenure of the NanoSphere Health Sciences board of directors in years:

1.8
Average Tenure
  • The average tenure for the NanoSphere Health Sciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mike Iverson

TITLE
Chairman of the Board
AGE
67
TENURE
0.2 yrs

Richard Kaufman

TITLE
Co-Founder
COMPENSATION
$146K
AGE
69
TENURE
1.8 yrs

Stephanie Hopper

TITLE
Director & COO
COMPENSATION
$3K
TENURE
1.8 yrs

David Theil

TITLE
Member of Board of Advisors – Scientific

Patricia Theil

TITLE
Member of Board of Advisors – Scientific

William Block

TITLE
Member of Board of Advisors – Scientific

David Carroll

TITLE
Member of Board of Advisors – Scientific

John Cavollo

TITLE
Member of Board of Advisors – Scientific

Joseph Purita

TITLE
Member of Board of Advisors – Scientific

Christine Peterson

TITLE
Member of Board of Advisors – Scientific
Who owns this company?
Recent Insider Trading
  • Information is not available.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
14. Aug 19 Sell David Sutton Individual 07. Aug 19 07. Aug 19 -150,000 CA$0.18 CA$-27,000
07. Aug 19 Buy Michael Iverson Individual 07. Aug 19 07. Aug 19 150,000 CA$0.18 CA$27,000
25. Feb 19 Buy Michael Iverson Individual 21. Feb 19 21. Feb 19 333,330 CA$0.30 CA$99,999
20. Jun 19 Buy Mark Percival Individual 06. Jun 19 06. Jun 19 43,333 CA$0.30 CA$13,000
01. Mar 19 Sell Preferred Holdings, Llc Company 27. Feb 19 27. Feb 19 -166,666 CA$0.30 CA$-50,000
19. Dec 18 Buy Preferred Holdings, Llc Company 17. Dec 18 17. Dec 18 1,166,666 CA$0.30 CA$350,000
07. Nov 18 Sell Preferred Holdings, Llc Company 01. Nov 18 01. Nov 18 -1,000,000 CA$0.35 CA$-350,000
X
Management checks
We assess NanoSphere Health Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NanoSphere Health Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NSHS News

Simply Wall St News

Such Is Life: How NanoSphere Health Sciences (CNSX:NSHS) Shareholders Saw Their Shares Drop 55%

View our latest analysis for NanoSphere Health Sciences NanoSphere Health Sciences recorded just US$302,941 in revenue over the last twelve months, which isn't really enough for us to consider it to have a proven product. … It seems likely some shareholders believe that NanoSphere Health Sciences will significantly advance the business plan before too long. … If you would like to research NanoSphere Health Sciences in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

Simply Wall St -

NSHS Company Info

Description

NanoSphere Health Sciences Inc., a nano-biotechnology company, focuses on providing delivery of nutritive elements and medicants through licensing arrangements. The company develops NanoSphere drug delivery system, a platform using nanotechnology in the bio delivery of supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, and animal health industries. NanoSphere Health Sciences Inc. is headquartered in Vancouver, Canada.

Details
Name: NanoSphere Health Sciences Inc.
NSHS
Exchange: CNSX
Founded:
CA$10,833,505
108,335,051
Website: http://www.nanospherehealth.com
Address: NanoSphere Health Sciences Inc.
1090 West Georgia Street,
Suite 488,
Vancouver,
British Columbia, V6E 3B7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX NSHS New Common Shares Canadian National Stock Exchange CA CAD 05. Dec 2017
OTCPK NSHS.F New Common Shares Pink Sheets LLC US USD 05. Dec 2017
DB 2CG2 New Common Shares Deutsche Boerse AG DE EUR 05. Dec 2017
Number of employees
Current staff
Staff numbers
0
NanoSphere Health Sciences employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:51
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.